Why are Healius shares crashing 35% on Wednesday?

This healthcare share is crashing deep into the red on Wednesday. What's happening?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Healius Ltd (ASX: HLS) shares are back from their trading halt and crashing deep into the red.

In morning trade, the healthcare company's shares are down 35% to $1.19.

As a comparison, the ASX 200 index is trading broadly flat.

A woman looks shocked as she drinks a coffee while reading the paper.

Image source: Getty Images

Why are Healius shares crashing?

Investors have been hitting the sell button today after the company completed the institutional component of a heavily discounted entitlement offer.

According to the release, the company has raised a total of approximately $154 million at $1.20 per new share. This represents a 35% discount to where Healius shares last traded.

The company notes that the institutional entitlement offer was well supported by existing Healius institutional shareholders. Approximately 92% of entitlements available to eligible institutional shareholders were taken up.

Entitlements not taken up by eligible institutional shareholders and entitlements of ineligible institutional shareholders were sold at the $1.20 per share offer price.

The company will now push ahead with a retail entitlement offer aiming to raise a further $33 million.

Why is it raising funds?

Healius will use the proceeds from the entitlement offer to reduce its net debt and reset its balance sheet with appropriate gearing.

This capital raising coincides with the company making an agreement with its lenders to waive its gearing covenant for the first half of 2024 and temporarily increase the covenant from 3.5 times to 4 times at 30 June 2024.

Following the completion of the entitlement offer, Healius expects to have sufficient financial flexibility and liquidity. Though, it is worth noting that part of the agreement will see the company suspend its dividend in FY 2024.

Following today's disappointing decline, Healius shares are now down approximately 64% over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Broker sees 26% upside in ASX healthcare share behind Chemist Warehouse

Morgans has just upgraded its rating on this ASX healthcare stock due to ongoing share price weakness.

Read more »

Woman using a pen on a digital stock market chart in an office.
Healthcare Shares

Why this ASX healthcare stock is surging while the market sinks on Middle East fears

Avita shares surge as a US government contract boosts sentiment again

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Healthcare Shares

Should you buy Telix shares after its big US news?

Is this milestone a reason to invest? Let's find out.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Up 31% in a month, why are Telix shares lifting off again on Friday?

ASX investors are piling into Telix shares today. But why?

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Where is the value amongst ASX healthcare shares?

These three stocks are worth monitoring.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Telix Pharmaceuticals: FDA accepts Pixclara NDA

The FDA has accepted Telix's Pixclara NDA for imaging brain cancer.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Bell Potter says this ASX healthcare stock could rise nearly 200%

The positive announcement has reinforced the broker's recommendation.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Healthcare Shares

CSL shares: 3 reasons to buy and 3 reasons to sell

CSL shares have tumbled again.

Read more »